Pricing Log in Create free account

Cellectis S.A. (CLLS) vs Novogen Limited (KZIA)

Cellectis S.A. and Novogen Limited are both Biotechnology companies. Cellectis S.A. and Novogen Limited are of similar size ($80.0M and $74.5M). Novogen Limited has the higher net margin (0.00% vs −102.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Novogen Limited leads on 11 and Cellectis S.A. on 1.

Valuation

Metric CLLS KZIA Biotechnology median
P/E n/m n/m 10.60
P/S 1.69 — 9.40
P/B 2.62 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 1.46 0.66
EV/Sales 0.23 n/m 9.02
Earnings yield (61.13%) (2.99%) (32.88%)
Free cash flow yield (42.90%) 0.00% (23.13%)

Profitability

Metric CLLS KZIA Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (90.88%) — 0.00%
Net margin (102.34%) 0.00% 0.00%
Free cash flow margin (68.63%) 0.00% 0.00%
Return on equity (94.54%) 0.00% (51.96%)
Return on assets (21.02%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLLS KZIA Biotechnology median
Revenue growth (TTM) 0.61% — 6.76%
EPS growth (last fiscal year) (63.41%) 63.24% 29.88%
Revenue growth, 5-year CAGR (0.70%) 11.56% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLLS KZIA Biotechnology median
Debt to equity 1.79 0.00 0.00
Current ratio 1.37 2.87 4.97
Net debt to EBITDA 9.54 0.30 1.01

Dividend

Metric CLLS KZIA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CLLS KZIA Biotechnology median
Market cap 74.50m 80.01m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack